Medtech fundraising and the FDA pathway in the room
A medtech raise is planned around the device's FDA route: 510(k), De Novo or PMA, each with its own evidence, cost and timeline. Put the regulatory strategy, the quality system and the reimbursement plan at the front, and keep design files and test data for investors in diligence.
Folder index
- 01 Overview Deck, product, clinical need, use of proceeds by regulatory milestone.
- 02 Regulatory strategy Device class, chosen pathway, predicate analysis, FDA pre-submission feedback.
- 03 Clinical evidence Bench, animal and clinical data, IDE status and study plans.
- 04 Quality system QMS manual, design controls, risk management file, audit history.
- 05 Reimbursement Coding, coverage and payment analysis, payer feedback.
- 06 Manufacturing Contract manufacturer agreements, bill of materials, cost model.
- 07 IP Patents, freedom to operate, invention assignments, licenses.
How this raise works
FDA sorts devices into Class I, II and III by risk. Many Class II devices reach the market through a 510(k), showing substantial equivalence to a legally marketed device. Novel low to moderate risk devices may use a De Novo request. Most Class III devices need premarket approval (PMA), which typically requires clinical evidence. Significant-risk device studies run under an investigational device exemption (IDE). The pathway sets how much capital the company needs before revenue.
Investors also check the quality management system. FDA's quality system regulation for devices (21 CFR Part 820) now incorporates ISO 13485 by reference, so investors ask for the QMS documentation, design controls and any FDA inspection history. Manufacturing partners and the bill of materials matter for margin.
Clearance alone does not create sales. Investors want to see coding, coverage and payment: whether a CPT or other code exists, which payers cover the procedure and what the hospital or physician earns. Many medtech raises are judged as much on the reimbursement plan as on the device.
Best data rooms for this raise
The 16 rooms re-ranked with this raise's weights. Permission control carries the most weight here.
- Investor tracking 22%
- Permission control 25%
- Raise workflow 23%
- Investor onboarding 14%
- Cost of a raise 16%
-
Full deal room with AI, a listed price and a 14-day free trial.
Price $149 a month Trial 14-day free trial Features 8 of 12 listed -
Long-running M&A platform with layered permissions and fast support.
Price Priced on request Trial Free trial available Features 9 of 12 listed -
Bank-grade platform for large processes, with AI and a mobile app.
Price Priced on request Trial Demo on request Features 10 of 12 listed -
Deal room with AI and readiness tools for preparing a process.
Price Priced on request Trial Free trial available Features 8 of 12 listed -
One of the oldest deal rooms, common on bank-led transactions.
Price Priced on request Trial Demo on request Features 8 of 12 listed -
Simple flat-rate deal room with signing and Q&A.
Price $250 a month Trial Free trial available Features 8 of 12 listed -
Easy, reliable deal room favored by mid-market advisers.
Price Priced on request Trial Free trial available Features 7 of 12 listed -
Deal room with a listed monthly price and an open API.
Price $299 a month Trial Free trial available Features 7 of 12 listed -
Content cloud with watermarks and signing, priced per user.
Price $15 a user a month Trial Free trial available Features 9 of 12 listed -
European deal room strong in real estate, with AI features.
Price Priced on request Trial Demo on request Features 8 of 12 listed
Places 11 to 16: ShareVault (7.0), SmartRoom (7.0), DealRoom (7.0), Venue by DFIN (6.3), Digify (6.1), DocSend (5.8)
Folder index for the room
A starting index for this raise. Number the folders so the order survives exports and investors can cite them in questions.
- 01 OverviewDeck, product, clinical need, use of proceeds by regulatory milestone.
- 02 Regulatory strategyDevice class, chosen pathway, predicate analysis, FDA pre-submission feedback.
- 03 Clinical evidenceBench, animal and clinical data, IDE status and study plans.
- 04 Quality systemQMS manual, design controls, risk management file, audit history.
- 05 ReimbursementCoding, coverage and payment analysis, payer feedback.
- 06 ManufacturingContract manufacturer agreements, bill of materials, cost model.
- 07 IPPatents, freedom to operate, invention assignments, licenses.
- 08 CommercialClinician feedback, pilot sites, distribution plan.
- 09 Corporate and capitalizationCharter, cap table, financing documents.
- 10 FinancialsBudget by milestone, runway, grants.
Features this raise needs
| Feature | Why | Ellty | iDeals | Datasite | Ansarada | Intralinks | SecureDocs |
|---|---|---|---|---|---|---|---|
| Q&A module | LPs and lead investors post questions on a file; the deal team routes each one, drafts a reply and decides who sees it. | ||||||
| View-only files | Files can be read but not saved or printed, and the setting can change mid-raise without a new invite. | ||||||
| Dynamic watermarks | Stamps the reader and a timestamp over every page, so a PPM that leaks carries its source with it. | ||||||
| Investor activity log | A per-investor record of opens, pages and minutes, which tells the IR team who is in diligence and who stalled. |
Setting up the room
- 01
Lead with the pathway
State the device class and route and link each funding tranche to a regulatory step.
- 02
Show FDA feedback
Include pre-submission minutes or letters so investors read FDA's view, not only yours.
- 03
Package the QMS
Organize quality documents so a reviewer can follow design controls from inputs to verification.
- 04
Prove the payment path
Add a reimbursement analysis with codes, coverage status and expected payment.
- 05
Stage design files
Keep detailed drawings and test data view-only for investors in confirmatory diligence.
Common mistakes
- Assuming a 510(k) when no suitable predicate device exists.
- No reimbursement analysis, leaving investors to guess at adoption.
- Quality documents assembled only after an investor asks for them.
Calculators for this raise
Or take the four-question quiz and check the raise checklist.
Questions and answers
How does the FDA pathway affect a medtech raise?
It sets the evidence, time and cost before sales. A 510(k) device usually needs less capital before revenue than a device that needs PMA and a pivotal clinical study.
What is the difference between 510(k), De Novo and PMA?
510(k) shows substantial equivalence to a marketed device; De Novo is for novel low to moderate risk devices with no predicate; PMA is the approval route for most high-risk Class III devices.
Do medtech investors review the quality system?
Yes. They ask for QMS documents, design controls, risk management and any inspection history.